Current Headlines
-
Ideal Option Opens Largest Outpatient Addiction Clinic And Lab In King County
3/11/2024
Ideal Option, a national leader in evidence-based outpatient treatment for addiction to fentanyl, heroin, methamphetamine, alcohol and polysubstance, has opened a 13,000-square-foot facility in Renton combining low-barrier treatment services with a state-of-the-art laboratory and community resource center.
-
The Jackson Laboratory And LG AI Research Partner To Pioneer Biomedical Advancements
3/11/2024
What can happen when prominent institutions in technology and research form a partnership to accelerate the implementation of artificial intelligence (AI) to enhance biomedical research and clinical care? A recent agreement in the field carries with it lofty aspirations.
-
Health Gorilla Partners With Wheel To Extend Diagnostic Ordering Through Wheel’s Virtual Care Ecosystem
3/7/2024
Health Gorilla, a Qualified Health Information Network™ (QHIN™) and interoperability solution provider, and Wheel, the virtual care platform powering the future of care, partner to extend seamless lab ordering workflows within the Wheel Virtual Care Platform.
-
Key Proteo Announces Clinical Laboratory Expansion Plans Including New CLIA-Certified Laboratory
3/7/2024
Key Proteo, a pioneering proteomics diagnostics company specializing in the early identification of rare but treatable genetic disorders, announced it has initiated plans to build a new CLIA-certified laboratory as part of its initial commercialization and growth strategy to enhance newborn screening programs.
-
Co-Diagnostics, Inc. JV CoSara Receives Clearance From Indian Regulators For Influenza Multiplex PCR Test
3/7/2024
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara Diagnostics Pvt Ltd ("CoSara," or the "JV"), its joint venture for manufacturing and sales in India, has received clearance by the Central Drugs Standard Control Organization ("CDSCO") in India to manufacture and sell its SARAPLEX™ Influenza Multiplex (IFM) Test Kit to clinical laboratories as an in vitro diagnostic ("IVD") for the detection and differentiation of Influenza A and Influenza B.
-
QuidelOrtho Receives Health Canada Approval For Quidel Triage PLGF Test For Laboratory Use In Canada
3/6/2024
QuidelOrtho Corporation (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, has received approval from Health Canada for its Triage PLGF test for laboratory use in Canada.
-
Cal-Tec Labs Inc. Acquired By Medical Technology Associates
3/6/2024
Cal-Tec Labs Inc. (CTL), a full-service calibration lab based in Pittsburgh, was acquired by Florida-based Medical Technology Associates (MTA), the national corporation announced today.
-
Ibex And PathPresenter Launch Partnership To Accelerate Adoption Of AI-Powered Digital Pathology
3/6/2024
Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, and PathPresenter, the global image sharing platform for pathology, today announced a partnership to advance the adoption of AI-powered digital pathology.
-
New Data Demonstrate Sunbird Bio’s APEX Diagnostic Test Accurately Differentiates Key Alzheimer’s Disease Biomarker In Blood
3/5/2024
Sunbird Bio, a biotechnology company developing proprietary protein- and blood-based technologies to improve diagnosis and treatment of neurological disorders and early-stage cancer, today announced new data demonstrating that their APEX (Amplified Plasmonic EXosomes) amyloid beta (Aβ) test, the company’s investigational blood-based diagnostic in Alzheimer’s disease, effectively discriminated between patients who were positive versus negative for Aβ on positron emission tomography (PET) scans.
-
Eisai Invests In C2N To Support Simplifying The Diagnosis Of Early Alzheimer's Disease To Better Serve Patients
3/5/2024
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that its U.S. subsidiary Eisai Inc. has decided to invest up to 15 million USD in C2N Diagnostics LLC (Headquarters: St. Louis, Missouri, the United States "C2N") to support C2N's efforts to expand the availability, accessibility, affordability and utilization of blood-based tests for the diagnosis of Alzheimer's disease (AD) in the U.S. This investment is in addition to the collaboration with C2N announced in August 2022 regarding the use of blood-based assays in the diagnosis of people living with dementia in clinical practice in the U.S.